Thierry Lomberget

Prof. Thierry Lomberget

UMR CNRS 5246 – ICBMS – COSSBA team, Université Lyon 1, 8, avenue Rockefeller, CEDEX 8, 69373 Lyon, France

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ABAlexandre Bancet
Alexandre Bancet
CRClaire Raingeval
Claire Raingeval
Thierry LombergetThierry Lomberget
Thierry Lomberget
Marc Le BorgneMarc Le Borgne
Marc Le Borgne
JGJean-francois Guichou
Jean-francois Guichou
IKIsabelle Krimm
Isabelle Krimm

28 January 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BBBenoît Bestgen
Benoît Bestgen
IKIsabelle Krimm
Isabelle Krimm
IKIrina Kufareva
Irina Kufareva
AKAhmed Ashraf Moustafa Kamal
Ahmed Ashraf Moustafa Kamal
WSWei Guang Seetoh
Wei Guang Seetoh
Thierry LombergetThierry Lomberget
Thierry Lomberget

28 January 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
BBBenoît Bestgen
Benoît Bestgen
IKIrina Kufareva
Irina Kufareva
WSWei Guang Seetoh
Wei Guang Seetoh
CAChris Abell
Chris Abell
RHRolf W. Hartmann
Rolf W. Hartmann
MEMatthias Engel
Matthias Engel
Protein CK2 has gained much interest as an anticancer drug target in the past decade. We had previously described the identification of a new allosteric site on the catalytic α-subunit, along with first small molecule ligands based on the 4-(4-phenylthiazol-2-ylamino)benzoic acid scaffold. In the present work, structure optimizations guided by a binding model led to the identification of the lead compound 2-hydroxy-4-((4-(naphthalen-2-yl)thiazol-2-yl)amino)benzoic acid (27), showing a submicromolar potency against purified CK2α (IC50 = 0.6 μM). Furthermore, 27 induced apoptosis and cell death in 786-O renal cell carcinoma cells (EC50 = 5 μM) and inhibited STAT3 activation even more potently than the ATP-competitive drug candidate CX-4945 (EC50 of 1.6 μM vs 5.3 μM). Notably, the potencies of our allosteric ligands to inhibit CK2 varied depending on the individual substrate. Altogether, the novel allosteric pocket was proved a druggable site, offering an excellent perspective to develop efficient and selective allosteric CK2 inhibitors.

1 January 2016 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CDCong Viet Do
Cong Viet Do
AFAbdelfattah Faouzi
Abdelfattah Faouzi
CBCaroline Barette
Caroline Barette
AFAmaury Farce
Amaury Farce
MFMarie-Odile Fauvarque
Marie-Odile Fauvarque
Thierry LombergetThierry Lomberget
Thierry Lomberget

1 April 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AFAbdelfattah Faouzi
Abdelfattah Faouzi
AAAlexandre Arnaud
Alexandre Arnaud
ABAlexandre Bancet
Alexandre Bancet
CBCaroline Barette
Caroline Barette
JPJordane Preto
Jordane Preto
Thierry LombergetThierry Lomberget
Thierry Lomberget

17 October 2024 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
AFAbdelfattah Faouzi
Abdelfattah Faouzi
AAAlexandre Arnaud
Alexandre Arnaud
FHFrançois Hallé
François Hallé
JRJean Roussel
Jean Roussel
MAMandy Aymard
Mandy Aymard
Thierry LombergetThierry Lomberget
Thierry Lomberget
A series of sulfur-containing tetracycles was designed and evaluated for their ability to inhibit protein kinase DYRK1A, a target known to have several potential therapeutic applications including cancers, Down syndrome or Alzheimer's disease. Our medicinal chemistry strategy relied on the design of new compounds using ring contraction/isosteric replacement and constrained analogy of known DYRK1A inhibitors, thus resulting in their DYRK1A inhibitory activity enhancement. Whereas a good inhibitory effect of targeted DYRK1A protein was observed for 5-hydroxy compounds 4i–k (IC50 = 35–116 nM) and the 5-methoxy derivative 4e (IC50 = 52 nM), a fairly good selectivity towards its known DYRK1B off-target was observed for 4k. In addition, the most active compound 4k, having an ATP-competitive mechanism of action, proved to be also a potent inhibitor of CLK1/CLK4 (IC50 = 20 and 26 nM) and, to a lesser extent, of haspin (IC50 = 76 nM) kinases. In silico docking studies within the DYRK1A, CLK1/CLK4 and haspin ATP binding sites were carried out to understand the interactions of our tetracyclic derivatives 4 with these targets. Antiproliferative activities on U87/U373 glioblastoma cell lines of the most potent compound 4k showed a moderate effect (IC50 values between 33 and 46 μM). Microsomal stabilities of the designed compounds 4a–m were also investigated, showing great disparities, depending on benzo[b]thiophene ring 5-substitution.